富煌鋼構(002743.SZ)擬配股募資不超7億元用於償還銀行貸款與補充流動資金
格隆匯10月18日丨富煌鋼構(002743.SZ)公佈,公司2019年度公開發行證券採用向原股東配售股份的方式進行,擬按每10股配售不超過3股的比例向全體股東配售。
預計募集資金總額不超過人民幣7億元,扣除發行費用後全部用於償還銀行貸款與補充流動資金,其中:不超過4億元用於償還銀行貸款;不超過3億元用於補充流動資金。
公司控股股東安徽富煌建設有限責任公司承諾以現金方式全額認購其可配售的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.